CHM chimeric therapeutics limited

0.00%

0.4¢

Ann: Phase 1/2 CHM CDH17 CAR-T GMP Manufacturing Complete, page-63

First 63 Last

Share
Profile

Follow
Steini

14,081 Posts.

4209

25/09/24

10:00

Post #: 75826109
Share

Originally posted by pfeifer1982: ↑

ALA's platform is based on a technology that - if their clinical data can deliver what their pre-clinical data appears to be suggesting - the one thing these kind of cancer patients don't have, which is a chance to get access to a treatment that does not require to be individually (and time consuming - see the timeline from recruitment to first patient dosed in our CDH17 trial) manufactured using their own cells (autologous), but instead could be readily available in a nearly limitless quantity off-the-shelf. Essentially no waiting time vs 4 weeks (currently). When the patient's life expectancy is measured in months not years, 4 weeks can make a huge difference.
The IND process should be fairly streamlined not just for the one product, but the pipeline once they get the nod on the iPSC process since the platform will utilise the same starting material, essentially eliminating or at least reducing the heterogenity that these types of (living) cell therapies bring with them. That in return should hopefully make the therapy more consistent and the effect on patients more predictable.
Once granted, they can easily apply for IND's in other areas as well based on promising pre-clinical data.

I can see the value, but as you said, they are still behind in terms of development, which also has something to do with the induced Pluripotent Stem Cell industry in general being fairly new. But it is VERY promising. And that's what ALA investor (not traders) are hoping for.

Expand

CHM's GBM and CDH17 CAR-Ts are autologous but its NK-cell platform is allogeneic. IMU's allogeneic Azer-Cel is years ahead of ALA's iNKT plus the progressed CF33 platform with ODD for bile duct cancer and much more and yet, just valued twice as ALA's tech. You have to admit, the whole valuations don't make any sense at all.

CHM Price at posting: 1.3¢ Sentiment: Hold Disclosure: Held
8 Upvote

0 Great analysis

Reply

Top Stories

SRL

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

RMX

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

OCC

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

PAR

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

MVF

Monash IVF shares cater 25% – Disaster or deep-value play?

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

First 63 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 0.4¢		Change 0.000(0.00%)		Mkt cap ! $8.060M

Open	High	Low	Value	Volume
0.4¢	0.4¢	0.4¢	$19.57K	4.893M

Buyers (Bids)

No.	Vol.	Price($)
4	419507	0.4¢

Sellers (Offers)

Price($)	Vol.	No.
0.5¢	18587873	22

View Market Depth

No.	Vol.	Price($)
4	419507	0.004
39	26659272	0.003
15	14700506	0.002
12	54600000	0.001
0	0	0.000

Price($)	Vol.	No.
0.005	17587873	20
0.006	13115184	13
0.007	3100000	2
0.008	8542434	6
0.009	2390797	5

Last trade - 15.59pm 27/06/2025 (20 minute delay)

CHM (ASX) Chart

Ann: Phase 1/2 CHM CDH17 CAR-T GMP Manufacturing Complete, page-63

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

Australia’s gas crisis is here – and dying coal plants aren’t helping

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Monash IVF shares cater 25% – Disaster or deep-value play?

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Phase 1/2 CHM CDH17 CAR-T GMP Manufacturing Complete, page-63

Top Stories

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

Australia’s gas crisis is here – and dying coal plants aren’t helping

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Monash IVF shares cater 25% – Disaster or deep-value play?

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News